Abstract:Puerarin is a potential therapeutic agent for cardiovascular diseases. But its poor oral bioavailability restricts Its clinical application. In present study, as an evaluation of a formulation to improve the bioavailability of the drug, puerarin and its phospholipid complex were given to rats by intragastrically (i.g.) administration to compare pharmacokinetic, tissue distribution, and excretion. Serum samples were obtained at designated times after a single oral dose of 400 mg/kg puerarin or its complex. Tissue samples (heart, liver, spleen, kidney, lung, and brain), urine, and feces were collected and analyzed by a sensitive and specific high. performance liquid chromatography (HPLC) method after i.g. administration of puerarin or its phospholipid complex. Compartmental and non-compartmental analyses were applied to the serum concentration versus time data. Pharmacokinetic parameters were calculated using the 3P97 pharmacokinetic software package. An open two-compartment, first-order model was selected for pharmacokinetic modeling. The results showed that after i.g. administration of 400 mg/kg puerarin and its phospholipid complex (equivalent to 400 mg/kg of puerarin), the pharmacokinetic parameters of the two formulations were different. The serum concentrations reached peaks at 0.894 +/- 0.521 h and 0.435 +/- 0.261 h, respectively, indicating the complex was more readily absorbed in serum than puerarin. The maximum concentrations for puerarin and its complex were 1.367 +/- 0.586 mg.L-1 and 2.202 +/- 1.28 mg.L-1 and AUC were 5.779 +/- 1.662 mg.h. L-1 and 8.456 +/- 0.44 mg.h L-1, respectively, indicating a higher bioavailability for the complex. The widely distribution characteristics of puerarin and its complex in tissues post-i.g. administration was identical and in a descending order as follows: lung, kidney, liver, heart, spleen, and brain. However, the amount was different. Puerarin distribution was higher in heart, lung, and brain after administering the complex. The cumulative 72 h urinary excretion of puerarin after i.g. administration of puerarin and its complex accounted for 1.05%, 1.11% of the administered dose, respectively. The cumulative feces excretion of puerarin was 32.3% and 25.5%. To sum up, oral administration of puerarin phospholipid complex modified the pharmacokinetics and tissue distribution of puerarin and it could be an effective oral formulation for puerarin.

Preparation and Evaluation of Puerarin-loaded PLGA Nanoparticles for Improving Oral Bioavailability in SD Rats

Preparation of puerarin solid lipid nanoparticles for oral administration

Enhancement of Oral Bioavailability of Puerarin by Polybutylcyanoacrylate Nanoparticles

Oral Bioavailability and Lymphatic Transport of Pueraria Flavone-Loaded Self-Emulsifying Drug-Delivery Systems Containing Sodium Taurocholate in Rats.

Enhanced Oral Bioavailability of Acetylpuerarin by Poly(lactide-Co-glycolide) Nanoparticles Optimized Using Uniform Design Combined with Response Surface Methodology

Improvement in Solubility and Bioavailability of Puerarin by Mechanochemical Preparation

Preparation, characterization and bioavailability of oral puerarin nanoparticles by emulsion solvent evaporation method

Preparation and Characterization of Puerarin-Loaded Lipid Nanocapsules

Formulation and Pharmacokinetics Evaluation of Puerarin Nanocrystals for Intravenous Delivery

Polysorbate 80‐coated PLGA nanoparticles improve the permeability of acetylpuerarin and enhance its brain‐protective effects in rats

In vitro evaluation and in situ intestinal absorption characterisation of paeoniflorin nanoparticles in a rat model

Puerarin Loaded PLGA Nanoparticles: Optimization Processes of Preparation and Anti-alcohol Intoxication Effects in Mice

Preparation and Release Rate in Vitro of Puerarin Enteric Nanoparticles

[Pharmacokinetics, pharmacodynamics, and tissue distribution of oral co-loaded puerarin/daidzein mixed micelles in rats]

Oral Delivery of Puerarin Nanocrystals to Improve Brain Accumulation and Anti-Parkinsonian Efficacy.

RGD Modified and PEGylated Lipid Nanoparticles Loaded with Puerarin: Formulation, Characterization and Protective Effects on Acute Myocardial Ischemia Model.

Nanoparticles Mediating the Sustained Puerarin Release Facilitate Improved Brain Delivery to Treat Parkinson's Disease

Effects of particle size on the pharmacokinetics of puerarin nanocrystals and microcrystals after oral administration to rat.

Pharmacokinetic, Tissue Distribution, and Excretion of Puerarin and Puerarin-Phospholipid Complex in Rats

Preparation, Characterization And Drug Release Of Biodegradable Solid Lipid Nanoparticles

Formulation Optimization and Bioavailability after Oral and Nasal Administration in Rabbits of Puerarin-Loaded Microemulsion